A Study to Investigate the Effectiveness, Safety, and Tolerability of MAG200 Solution for Intra-articular Injection Compared With Placebo in Participants Aged 35 to 75 Years of Age With Symptomatic Osteoarthritis of the Knee.

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

573

Participants

Timeline

Start Date

November 30, 2025

Primary Completion Date

February 29, 2028

Study Completion Date

February 28, 2030

Conditions

Knee Osteoarthristis

Interventions

BIOLOGICAL

allogeneic human adipose-derived mesenchymal stem cells

The Investigational Product MAG200 is a preparation of 5 mL allogeneic human adipose-derived mesenchymal stem cells (MSCs).

OTHER

Placebo

Placebo is commercially available injectable normal saline (0.9% Sodium Chloride in Water for Injection)

All Listed Sponsors

lead

Magellan Stem Cells

INDUSTRY